ClinicalTrials.gg
RecruitingNCT06810778Updated Jul 17, 2026

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

A Phase 1/2 interventional study of Duvelisib and Venetoclax in T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, sponsored by Jonsson Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Jonsson Comprehensive Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Leukemia, Prolymphocytic, T-Cell · United States.

Planned enrollment
20th of 23
12 · median 30
Started
2025
the only one that year
Phase 1/2
3 of 24
2 open now
Registered
22nd of 24
by date
Lead sponsor
1 of 24
Jonsson Comprehensive Cancer Center

Among the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, this one is the 20th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1/2, and was the 22nd registered.

Leukemia, Prolymphocytic, T-Cell

30 studies on the registry are indexed under Leukemia, Prolymphocytic, T-Cell; 8 are open to participants now.

Browse Leukemia, Prolymphocytic, T-Cell studies →

Open to participants now

6 of the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Leukemia, Prolymphocytic, T-Cell studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.

Read the detailed description

In this phase I/II trial, we combine duvelisib and venetoclax in patients with relapsed/refractory Peripheral T-cell lymphoma (PTCL). Researchers aim to determine the maximum tolerated doses (MTD) of duvelisib in combination with venetoclax, the safety of combination therapy, and preliminary efficacy data in Peripheral T-cell lymphoma (PTCL).

Patients with PTCL would be offered the option to remain on treatment beyond 2 years if they are clinically benefitting, complete response, partial response, stable disease (CR, PR, SD).

The phase I portion of the trial will determine the dose, schedule, safety, and tolerability of duvelisib in combination with venetoclax.

Phase I:

In the phase I study, 2 dose levels of duvelisib (15 and 25 mg BID) and 3 dose levels of venetoclax (200, 400, and 800 mg QD) will be evaluated. Patients will start with 15 mg BID of duvelisib and 200 mg QD of venetoclax. We use a traditional 3 + 3 design to accrue patients to each combination cohort. There are 5 possible dosing combinations to be tested, with up to 18 patients planned to be enrolled. Enrollment may stop early based on DLTs. The DLT assessment window is defined as Day 1-21 of Cycle 1 (21 days). De-escalation will occur if unexpected toxicity is observed and both drugs will be reduced for the next lower dosing cohort. Increasing drug dosing levels will be performed in parallel cohorts, each increasing either venetoclax or duvelisib (see Dosing Schema).

The following lymphoma subtypes will be excluded due to potential tumor lysis risk: cutaneous T-cell lymphoma (CTCL) and T-cell-prolymphocytic leukemia (TPLL).

Patients in the initial dosing cohorts will start at a lower dose of venetoclax than the tested dose in phase 2 trials dose (800 mg QD) and at a lower dose of duvelisib than the recommended phase 2 dose (25 mg BID). Once the RP2D of combination duvelisib plus venetoclax is determined, patients assigned to lower dose levels in the phase I trial will have the option to escalate their duvelisib and venetoclax doses to the RP2D.

Planned Phase II (dependent on phase I data and new discussions with AbbVie and Secura Bio):

The phase II study will only proceed after discussion of Phase I results with study investigators, DSMB, AbbVie, and Secura Bio and will enroll patients with relapsed/refractory PTCL at the RP2D.

Phase II will start once phase I data have been reviewed by AbbVie and Secura Bio, DSMB, and FDA, and proceeding to the next phase has been approved.

Study visits will occur weekly through cycles 1-2, once per cycle during cycles 3-7, every 2 cycles from cycle 8-13, and every 3 cycles thereafter.

03

Conditions studied

  • T-cell-prolymphocytic Leukemia
  • Cutaneous T-Cell Lymphoma Refractory

Keywords

  • leukemia
  • refractory
  • relapsed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase I: confirmed PTCL, except the following lymphoma subtypes: cutaneous T-cell lymphoma (CTCL) and T-cell-prolymphocytic leukemia (TPLL).
  • Phase II: same as phase I
  • Disease that has progressed during or relapsed after at least two previous therapies.
  • performance status ≤ 2
  • Adequate hepatic function defined as:

    o Serum (AST) and alanine transaminase (ALT) ≤ 3.0 x (ULN), ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin

  • Adequate renal function as defined by:

    o ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection

  • Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement confirmed on :

    • ≥ 1500 cells/mm3 (1.5 x 109/L) or ≥ 1000 cells/mm3 (1.5 x 109/L) with bone marrow involvement. Growth factor use is allowed in order to achieve this
    • count ≥ 50,000 cells/mm3 (50 x 109/L) independent of transfusion within 7 days of screening
    • ≥8 g/dL (without transfusion support.)

Exclusion criteria

Exclusion Criteria:

  • Phase I and Phase II:

    • Patients eligible for Hematopoietic stem cell transplantation ()
    • Cutaneous T-cell lymphoma (CTCL) and T-cell-prolymphocytic leukemia (TPLL)
    • Suspected and confirmed central nervous system involvement
    • Previous treatment with venetoclax or a PI3K inhibitor.
    • Active other than NHL requiring ongoing therapy, with the exception of hormonal therapy (i.e. castration-sensitive prostate cancer stable on testosterone blockade)
    • Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, surgery) within 2 weeks of Cycle 1/Day 1 with the following exceptions:

      • For patients on targeted therapies, a of least five half-lives is required
      • Patients who experience clinical deterioration may start therapy after a shorter washout period with prior approval by the PI
      • therapy (prednisone or equivalent \<20 mg daily) is allowed
      • Patients with multiple basal cell carcinomas that undergo sequential Moh's excisions with interim observation
    • Allogeneic hematologic stem cell transplant within 6 months of starting study treatment or active graft vs. host disease () requiring treatment or prophylaxis

      o Patients with a history of an allogeneic stem cell transplant > 6 months prior to starting study treatment should be stable, off of for at least 2 months.

    • Any active systemic infection requiring systemic antibiotics or other uncontrolled, active infections
    • Positive (HIV), virus (HCV), or virus (HBV) antibody test

      o For HCV and HBV, patients with evidence of prior infection also excluded

    • Evidence of other uncontrolled condition(s) including, but not limited to:

      • Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
      • Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate
    • Uncontrolled, not disease-related hemolytic anemia or ITP
    • History of stroke or intracranial hemorrhage
    • History of severe bleeding disorder (hemophilia A or B, von Willebrand disease (VWD)), history of spontaneous bleeding requiring blood transfusions or other medical intervention, history of life-threatening hemorrhage within 3 months of first dose.
    • Currently active gastrointestinal disease, including colitis, inflammatory bowel disease and diarrhea requiring therapy
    • Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment
    • Cardiac history of CHF requiring treatment or ≤ 50% or chronic stable angina
    • Use of Coumadin for anticoagulation (other anticoagulants permitted)
    • Lactating or pregnant
    • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction resulting in malabsorption or chronic diarrhea
    • Concurrent administration of medications or foods that are strong inhibitors or inducers of (see Appendix D)
    • Treatment with any of the following within 7 days prior to the first dose of study drug:
    • Steroid therapy for anti-neoplastic intent (defined as prednisone or equivalent >20 mg daily)
    • Moderate or strong cytochrome P450 3A (CYP3A) inhibitors (see Appendix D for examples)
    • Moderate or strong CYP3A inducers (see Appendix D for examples)
    • Administration or consumption of any of the following within 7 days prior to the first dose of study drug:

      • Grapefruit or grapefruit products
      • Seville oranges (including marmalade containing Seville oranges)
      • Star fruit
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Arm Treatment (Duvelisib and Venetoclax)

    Phase I: In the phase I study, 2 dose levels of duvelisib (15 and 25 mg BID) and 3 dose levels of venetoclax (200, 400, and 800 mg QD) will be evaluated. Patients will start with 15 mg BID of duvelisib and 200 mg QD of venetoclax. We use a traditional 3 + 3 design to accrue patients to each combination cohort. There are 5 possible dosing combinations to be tested, with up to 18 patients planned to be enrolled. Enrollment may stop early based on DLTs. The DLT assessment window is defined as Day 1-21 of Cycle 1 (21 days). De-escalation will occur if unexpected toxicity is observed and both drugs will be reduced for the next lower dosing cohort. Increasing drug dosing levels will be performed in parallel cohorts, each increasing either venetoclax or duvelisib.

    Drug: Duvelisib · Drug: Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Determine the dose limiting toxicities (DLTs), for the combination regimen of duvelisib plus venetoclax for patients with relapsed or refractory PTCL

    Phase I: Will be graded according to the Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 21 days

  2. Determine the Maximum Tolerated Dose MTD)

    Phase I: Will be defined as the highest dose studied for which the observed incidence of DLT is less than 33%. Frequencies of toxicities will be tabulated according to the National Cancer Institute Common Toxicity Criteria.

    Time frame: Up to 21 days

  3. Recommended phase II dose (Phase I)

    Phase I

    Time frame: Up to 21 days

Secondary outcomes

  1. Overall response rate

    Phase II: Will be assessed according to Lugano criteria. Will be based on exact one-sided binomial tests (Simon two-stage designs) within each of the disease groups. Will be estimated with exact 95% confidence intervals.

    Time frame: up to 1 year

  2. Objective response rate

    Phase II: Will be defined as proportion of patients who achieve a complete and partial response. Will be estimated along with a 95% confidence interval

    Time frame: Up to 1 year

  3. Duration of response

    Phase II: Will be calculated using Kaplan-Meier methodology.

    Time frame: From the date of response to the date of progression of disease, assessed up to 1 year

  4. Progression free survival

    Phase II: Will be calculated using Kaplan-Meier methodology.

    Time frame: From start of treatment to the date of progression, death or last follow-up, assessed up to 1 year

  5. Overall survival

    Phase II: Will be calculated using Kaplan-Meier methodology.

    Time frame: From the start of treatment to the date of death or last follow-up, assessed up to 1 year

  6. Pharmacokinetic parameters: Half-life

    Phase II: Will include half-life determined using non-compartmental methods. Standard descriptive statistics (mean, standard deviation, median, range) will be presented on all parameters.

    Time frame: At days 1, 8, and 15 of cycle 1 (1 cycle = 21 days)

  7. Pharmacokinetic parameters: Maximum concentration

    Phase II: Will include maximum concentration determined using non-compartmental methods. Standard descriptive statistics (mean, standard deviation, median, range) will be presented on all parameters.

    Time frame: At days 1, 8, and 15 of cycle 1 (1 cycle = 21 days)

  8. Pharmacokinetic parameters: Area under the curve

    Phase II: Will include area under the curve determined using non-compartmental methods. Standard descriptive statistics (mean, standard deviation, median, range) will be presented on all parameters.

    Time frame: At days 1, 8, and 15 of cycle 1 (1 cycle = 21 days)

  9. Pharmacokinetic parameters: Volume of distribution

    Phase II: Will include volume of distribution determined using non-compartmental methods. Standard descriptive statistics (mean, standard deviation, median, range) will be presented on all parameters.

    Time frame: At days 1, 8, and 15 of cycle 1 (1 cycle = 21 days)

  10. Pharmacokinetic parameters: Clearance

    Phase II: Will include clearance determined using non-compartmental methods. Standard descriptive statistics (mean, standard deviation, median, range) will be presented on all parameters.

    Time frame: At days 1, 8, and 15 of cycle 1 (1 cycle = 21 days)

07

Study locations

1 of 1 sites recruiting
  • David Geffen School of Medicine at the University of California at Los Angeles
    Los Angeles, California 90095-1406, United States
    Recruiting
    • Vanessa Crowell · Contactvcrowell@mednet.ucla.edu · 424-440-0843
    • Vladimir Bonhomme · Contactvbonhomme@mednet.ucla.edu · 310-794-6500
    • Sven de Vos, MD, PhD · Principal investigator
    • John Timmerman, MD · Sub investigator
    • Patricia Young, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2030, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 6, 2025
StartActual
May 2, 2025
Primary completionEst.
Jun 1, 2030
CompletionEst.
Jun 1, 2031
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06810778
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
May 2, 2025
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Jul 17, 2026

Study contacts

Vladimir Bonhomme
Contact
VBonhomme@mednet.ucla.edu
310-794-6500
Vanessa Crowell
Contact
vcrowell@mednet.ucla.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Duvelisib · Venetoclax

Start the discussion